Key statistics
On Friday, Dyne Therapeutics Inc (DYN:NSQ) closed at 16.80, -32.80% below its 52-week high of 25.00, set on Oct 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 17.09 |
|---|---|
| High | 17.49 |
| Low | 16.40 |
| Bid | 16.00 |
| Offer | 16.85 |
| Previous close | 16.55 |
| Average volume | 1.92m |
|---|---|
| Shares outstanding | 161.59m |
| Free float | 160.35m |
| P/E (TTM) | -- |
| Market cap | 2.67bn USD |
| EPS (TTM) | -3.66 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
- Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
- Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
- Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Dyne Therapeutics to Present at Upcoming Investor Conferences
More ▼
